Journal of Histopathology and Cytopathology
January 2024 Volume 8 Issue 1
Original Contribution
Evaluation of PD-L1 Immunoexpression in Resected Samples of Colorectal Adenocarcinoma: A Study on 64 Cases
1. *Dr. Israt Jahan, Lecturer, Department of Pathology, Chandpur Medical College, Chandpur, Bangladesh; isratliza424@gmail.com
2. Dr. Bishnu Pada Dey, Associate Professor, Department of Pathology, BSMMU, drbishnu@bsmmu.edu.bd
3. Dr. Md. Akhtaruzzaman, Lecturer, Department of Pathology, Pabna Medical College, Pabna, Bangladesh; akter22nd@gmail.com
4. Dr. Kassim Hagi Hussain, Senior lecturer, Department of pathology, Jazeera University Medical College, Somalia; doctorqaasim@gmail.com
5. Dr. Mahabub Alam, Assisstant Professor, Department of Pathology, Bashundhara Ad-din Medical College & Hospital, Dhaka, Bangladesh; mahabub.robin@gmail.com
6. Dr. Md Zillur Rahman, Professor, Department of Pathology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbagh, Dhaka-1000, Bangladesh;drzillur@bsmmu.edu.bd
*For correspondence
Abstract
Background: Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide and its incidence is rising steadily in developing nations. The patient prognosis for CRC remains poor, despite advances in surgery and treatment. Additionally, there are currently no reliable prognostic approaches for CRC, despite the use of conventional prognostic factors. Immune checkpoints blockades (ICB) have emerged as a promising treatment strategy and have dramatically improved long-term survival in several malignances. The “PD-1 (programmed cell death-1)”/PD-L1 (programmed cell death-ligand 1) axis plays an important role to control immune suppression by down-regulating T effector cell activities enable tumor cells to escape from the host’s anti-tumor immune surveillance. Aim of this study was to evaluate the expression of PD-L1 (28-8 clone) in resected samples of colorectal cancer.
Methods: This was a cross-sectional observational study. A total 64 cases were selected from the patients who were diagnosed as adenocarcinoma from resected samples received in the department of pathology at BSMMU from July 2021 to June 2023. Immuno-histochemical staining for PD-L1 was performed along with appropriate positive control.
Results: In this study PD-L1 immuno-expression was found in 14 (21.9%) out of 64 cases. However, no expression was found in rest of the 50 (78.1%) cases.
Conclusion: Evaluation of expression of PD-L1 may emerge as a new marker and target for the immunotherapy of colorectal cancer.
[Journal of Histopathology and Cytopathology, 2024 Jan; 8 (1):56-64]
DOI: https://www.doi.org/10.69950/jhc.2024.v8.i1.08
Keywords: CRC, ICB, PD-1, PD-L1, IRS.
Download Full
